Evidence map›Paper›PMID 40265482›Full record

ArticleAnnals of neurology2025

Association Between Vascular NOTCH3 Aggregation and Disease Severity in a CADASIL Cohort - Implications for NOTCH3 Variant-Specific Disease Prediction.

Minne N Cerfontaine, Gido Gravesteijn, Remco J Hack, Kyra L Dijkstra, Mar Rodríguez-Girondo, Benno Gesierich, Marie-Noëlle W Witjes-Ané, Remco van Doorn, Marco Duering, Julie W Rutten and 1 more

Abstract read
In one paragraph

Article in Annals of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Clinical Impact of NOTCH3 Variant Location After First Stroke in CADASIL.Annals of clinical and translational neurology · 2026
    Article
  3. NOTCH3 CADASIL Variant Receptor Aggregation Requires NOTCH3 Wild-Type Receptors: Identification of Highly Selective Inhibitors That Block the Process.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Minne N CerfontaineDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9357-270X
Gido GravesteijnDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-2610-8728
Remco J HackDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9302-5802
Kyra L DijkstraDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Mar Rodríguez-GirondoDepartment of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Benno GesierichMedical Image Analysis Centre (MIAC) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Marie-Noëlle W Witjes-AnéDepartment of Geriatrics and Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands.
Remco van DoornDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
Marco DueringMedical Image Analysis Centre (MIAC) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Julie W Rutten *Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
Saskia A J Lesnik Oberstein *Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Funding

Hersenstichting DR-2023-00420Hersenstichting HA2016-02-03ZonMw 09150182310003ZonMw 91717325
6 · The paper itself

Abstract

objectiveVascular NOTCH3 protein ectodomain aggregation is a pathological hallmark of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a monogenic small vessel disease typically caused by cysteine-altering variants in NOTCH3. Given their high population frequency, these NOTCH3 variants are an important genetic contributor to stroke and vascular dementia worldwide. Disease severity in CADASIL is highly variable and is mainly determined by the position of the pathogenic NOTCH3 variant in the NOTCH3 ectodomain. Here, we aimed to investigate the association between NOTCH3 aggregation load in skin vessels, cysteine-altering NOTCH3 variants, and disease severity in a prospective cohort study of 212 patients with CADASIL with 39 distinct cysteine-altering NOTCH3 variants.

methodsNOTCH3 aggregation load in skin vessels was determined by calculating the NOTCH3 score; the fraction of skin vessel wall area positive for NOTCH3 staining. Variant-specific NOTCH3 scores were calculated for variants present in 10 or more participants, by averaging the NOTCH3 scores of individuals with that distinct variant. The associations between the NOTCH3 score, NOTCH3 variants, and neuroimaging and clinical outcomes were investigated using multivariable linear mixed models, Cox regression, and mediation analyses.

resultsThe NOTCH3 score was significantly associated with lifetime stroke probability and small vessel disease neuroimaging outcomes, but not with age. Variant-specific NOTCH3 scores reflected differences in disease severity associated with distinct NOTCH3 variants.

interpretationThese findings suggest that differences in NOTCH3 aggregation propensity underlie the differences in disease severity associated with NOTCH3 cysteine-altering variants, and show that NOTCH3-variant specific NOTCH3 scores can contribute to improved individualized disease prediction in CADASIL. ANN NEUROL 2025;98:273-285.

Indexed as

CADASILReceptor, Notch3AdultAgedCohort StudiesFemaleHumansMaleMiddle AgedProspective StudiesSeverity of Illness IndexSkinNOTCH3 protein, humanReceptor, Notch3

Identifiers

PMID40265482
PMCPMC12278194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.